2-2--(hydroxynitrosohydrazono)bis-ethanamine has been researched along with Colonic-Neoplasms* in 2 studies
2 other study(ies) available for 2-2--(hydroxynitrosohydrazono)bis-ethanamine and Colonic-Neoplasms
Article | Year |
---|---|
In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF.
Tumor cells develop mechanisms that dysregulate apoptotic pathways resulting in resistance to cytotoxic stimuli. Primary SW480 and metastatic SW620 colon cancer cells are resistant to CDDP-induced apoptosis. Apoptosis-inducing factor (AIF) was significantly downregulated in SW620 compared to SW480 cells; while apoptotic mediators such as Bax, Bcl-2, and Bcl(XL) were not altered in these cell lines. Examination of tumor tissues from patients with colon cancer demonstrated a significant downregulation of AIF in patients with advanced disease. The role of AIF expression in resistance was examined. Several lines of evidence suggest the involvement of AIF expression level in the sensitivity of SW620 to CDDP-induced apoptosis: (1) sensitization of SW620 by the NO donor DETANONOate to CDDP-induced apoptosis correlated with the induction of AIF as assessed by RT-PCR and Western blot analysis, (2) treatment of SW620 cells with siRNA AIF, but not with control siRNAs, inhibited DETANONOate-induced sensitization to CDDP apoptosis, (3) sensitization by DETANONOate observed in vitro was corroborated in vivo in nude mice bearing SW620 tumor xenografts and treated with the combination of DETANONOate and CDDP, and (4) tumor tissues derived from the SW620 xenografts revealed significant upregulation of AIF and increased apoptosis by DETANONOate and CDDP combination treatment. Altogether, these findings underscore the potential therapeutic application of NO donors and subtoxic chemotherapeutic drugs in the treatment of advanced colon cancer resistant to conventional chemotherapeutic agents. Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Therapy, Combination; Humans; Mice; Neoplasm Metastasis; Nitric Oxide Donors; Nitroso Compounds; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2009 |
Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells.
Beta-catenin plays an important role in colonic tumorigenesis whereas inducible nitric oxide synthase and nitric oxide are elevated in colonic inflammation. Resistance of colonic epithelial cells to the induction of apoptosis may contribute to tumor development. Nitric oxide can stimulate apoptosis and, paradoxically, is implicated in the development of colon cancer. Our hypothesis was that beta-catenin could increase the resistance of colonic cancer cells to nitric oxide-induced apoptotic cell death. Here we show, using a beta-catenin overexpression system, that increased cytosolic beta-catenin renders colonic epithelial cells more resistant to nitric oxide-induced apoptotic cell death, independently of nitric oxide-induced accumulation of p53. Furthermore, we show that this occurs through inhibition of nitric oxide-induced release of cytochrome c from mitochondria and by blocking both the nitric oxide-induced suppression of the antiapoptotic protein, Bcl-xL, and the phosphorylation of Akt. We contend that increased nitric oxide production, such as that which occurs in chronic colonic inflammation, may select the cells with oncogenic mutant beta-catenin regulatory genes and contribute to human colonic carcinogenesis and tumor progression. Topics: Apoptosis; bcl-X Protein; beta Catenin; Cell Line, Tumor; Colonic Neoplasms; Humans; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Proto-Oncogene Proteins c-akt; Transfection; Tumor Suppressor Protein p53 | 2005 |